Adiposity Rebound Timing in Small for Gestational Age Children Treated With Growth Hormone: Results From LG Growth Study Data.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

This study analyzed data from a multicenter observational clinical trial (LG Growth Study) to determine AR timing in children born SGA without catch-up growth (CUG) who were treated with growth hormone (GH) therapy.

Why It Was Studied

Although studies have evaluated AR timing in Korean children, none has focused on children born small for gestational age (SGA).

Who Took Part

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

Although studies have evaluated AR timing in Korean children, none has focused on children born small for gestational age (SGA).

Topics PubMed links to this paper include Infant, Small for Gestational Age, Adiposity, Human Growth Hormone, Body Mass Index, Body Height and Puberty.

Author keywords: Time.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of Korean medical science), a journal based in Korea (South).

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.